Open AccessTreatment of Latent Tuberculosis Infection
Author(s) -
Dominik Zenner,
Netta Beer,
Ross Harris,
Marc Lipman,
Helen R. Stagg,
Marieke J. van der Werf
Publication year - 2017
Publication title -
annals of internal medicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 3.839
H-Index - 390
eISSN - 1539-3704
pISSN - 0003-4819
DOI - 10.7326/m17-0609
Subject(s) - medicine , pyrazinamide , isoniazid , rifampicin , latent tuberculosis , rifapentine , tuberculosis , odds ratio , randomized controlled trial , mycobacterium tuberculosis , pathology
Treatment of latent tuberculosis infection (LTBI) is an important component of tuberculosis (TB) control, and this study updates a previous network meta-analysis of the best LTBI treatment options to inform public health action and programmatic management of LTBI.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom